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Background: Cognitive impairment strikingly reduces the quality of life of Parkinson’s disease (PD) patients. Studies
find that pathological proteins, neuroinflammatory factors and free radicals may involve in the pathogenesis of
cognitive impairment of PD, however, results are inconclusive.
Methods: We recruited 62 PD patients and 31 healthy controls. PD patients were identified with cognitive
impairment, including PD with mild cognitive impairment (PD-MCI) and PD with dementia (PDD) according to the
diagnostic criteria for PD-MCI and PDD issued by Movement Disorder Society Task Force. The levels of pathological
proteins, including β-amyloid 1–42 (Aβ1-42),Total-tau (T-tau) and phosphorelated tau (P-tau), neuroinflammatory
factors,including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interferon-γ (INF-γ) and
prostaglandin E2 (PGE2), free radicals, including hydroxyl radical (·OH), hydrogen peroxide (H2O2) and nitric oxide
(NO) in cerebrospinal fluid(CSF) were detected. The levels of above factors in CSF were compared among healthy
controls and patients with and without cognitive impairment. Correlation analyses were performed between
Montreal Cognitive Assessment (MoCA) score and the levels of above factors in CSF.
Results: T-tau level in CSF from PD-CI patients are significantly elevated comparing with those without cognitive
impairment and controls (P = 0.016 and 0.004, respectively). The levels of P-tau (S396) and · OH in PD-CI patients
are significantly higher than controls (P = 0.001 and 0.014, respectively). IL-6 levels in PD-CI patients are strikingly
enhanced comparing with those without cognitive impairment (P = 0.005). MoCA score is negatively correlated
with the levels of T-tau (r = −0.340), P-tau (S396) (r = −0.448), IL-6 (r = −0.489) and · OH (r = −0.504) in PD-CI
patients.
Conclusions: Elevated levels of T-tau, P-tau (S396), IL-6 and · OH in CSF are significantly correlated with cognitive
impairment in PD patients. This investigation may suggest the potential biomarkers relating pathological proteins,
neuroinflammatory factors and free radicals in PD patients with cognitive impairment.
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Cognitive impairment (CI) is one of common non-motor
symptoms in Parkinson’s disease (PD), which develops
with the progression of PD. Mild cognitive impairment
(MCI) is an early stage of CI in PD patients with an esti-
mated prevalence of 20%-25% [1]. PD individuals with
MCI have an increased risk of developing dementia, which
occurs in the later stage of PD. The conversion rate from
MCI to dementia in PD patients is about 6%-15% annually
[2]. PD with dementia (PDD) strikingly reduces the quality
of life of PD patients, enormously enhances financial
burdens for their families and greatly causes life stresses
for their caregivers. Early diagnosis and intervention of PD
with MCI (PD-MCI) may delay its conversion to PDD.
Studies find that pathological hallmarks of Alzheimer’s
disease (AD), such as β-amyloid (Aβ) and tau, are demon-
strated to be linked with the risk of developing dementia
[3] in PD patients. However, roles of above pathological
proteins on PD-CI are not fully understood yet.
Neuroinflammation characterized by microglial activa-
tion serves as an engine driving PD progression. In sub-
stantia nigra, many endogenous and exogenous factors
activate microglia and produce neuroinflammatory factors
[4], such as tumor necrosis factor-α (TNF-α), interleukin-
1β (IL-1β), interleukin-6 (IL-6), interferon-γ (INF-γ) and
prostaglandin E2 (PGE2), which cause dopaminergic neur-
onal death. The dead neurons release iron, aggregated α-
synuclein and neuromelanin into the extracellular spaces
and provoke neuroinflammation by activating surrounding
microglia [5], propagating progressive degeneration of
dopaminergic neurons and deterioration of motor symp-
toms of PD. Recently, the significance of neuroinflamma-
tion in PD pathology extends beyond substantia nigra and
neuroinflammation impairs regions relevant to non-motor
symptoms [6]. However, there are few investigations on
the role of neuroinflammation in the development and
progression of PD with cognitive impairment (PD-CI) and
the relationship between the pathological proteins and
neuroinflammation in PD-CI is unclear yet.
Oxidative stress featured by the robust productions of
highly toxic free radicals plays a pivotal role on cognitive
decline in human with neurodegenerative diseases and
PD animal model. An animal experiment shows positive
correlations of spatial memory deficits with indicators of
oxidative stress in rat PD model treated with lipopolysac-
charide alone or plus 6-hydroxydopamine [7]. Lycopene
protects against cognitive decline through inhibition of
oxidative stress in rotenone-induced PD model [8]. These
data indicate a critical role of oxidative stress on cognitive
impairment in neurodegenerative diseases. However, there
is no investigation on the relationships between PD-CI
and free radicals in patients.
We hypothesize that the deposition of above patho-
logical proteins in cognition-associated regions may, onone hand, activate microglia and produce neuroinflam-
matory factors, and on the other hand, cause oxidative
stress and generate free radicals, leading to neuronal
damage and cognitive impairment. To test this hypoth-
esis, in this study, we assessed cognitive function for PD
patients, detected the levels of pathological proteins,
neuroinflammatory factors and free radicals in cerebro-
spinal fluid (CSF) from PD patients, and analyzed the
relationships between cognitive impairment and above
factors with aim to figure out the potential mechanisms
and biomarkers associated with the development and
severity of cognitive impairment in PD patients.
Methods
Subjects
We recruited 62 PD patients consecutively from the
Department of Neurology, Beijing Tiantan Hospital,
Capital Medical University from April 2010 to December
2013. Patients were diagnosed with PD according to UK
Parkinson’s Disease Society Brain Bank criteria [9]. Total
36 patients had PD-CI, 33 of which were with MCI and
3 cases were with dementia according to the criteria for
PD-MCI [10] and PDD [11], respectively. Cognitive
functions of PD-CI patients were evaluated with the items
from Montreal Cognitive Assessment (MoCA) and Mini-
Mental Status Examination (MMSE), including sevens
backwards, lexical fluency, clock drawing, pentagons and
word recall, as well as informant interview and Pill Ques-
tionnaire. Patients with other primary explanations for cog-
nitive impairment (e.g., delirium, stroke, major depression,
metabolic abnormalities, adverse effects of medication, or
head trauma) and PD-associated comorbid conditions (e.g.,
motor impairment or severe anxiety, depression, excessive
daytime sleepiness, or psychosis) that, in the opinion of
the clinician, significantly influence cognitive testing were
excluded. The remaining 26 PD patients were without
cognitive impairment (PD-NCI).
We recruited 31 normal controls consecutively based
on the following criteria: no neurological symptoms and
signs; no essential tremor, PD, secondary parkinsonism
and Parkinson’s plus syndrome; no cognitive impairment
and dementia; no systemic infectious diseases; no enceph-
alitis, meningitis, cerebrovascular disease, brain tumors
and other intracranial diseases; no surgical history; no
dysarthria and mental illness that can effect expression;
head MR is normal. The average age of control group
was matched with that of PD group.
This study was approved by Beijing Tiantan Hospital
Review Board. Written informed consents were obtained
from participants or their guardians if they had dementia.
CSF collection
Anti-parkinsonian drugs were withheld for 12–14 hours
if patients’ condition allowed. We collected 3 ml CSF
Yu et al. BMC Neurology 2014, 14:113 Page 3 of 7
http://www.biomedcentral.com/1471-2377/14/113under fasting condition through lumbar puncture,
followed by being centrifuged in 4°C at 3000 r/min for
10 minutes. Supernatant was then preserved at −80°C
for detection.
Detections of pathological proteins, neuroinflammatory
factors and free radicals
Pathological proteins
The levels of Aβ1-42, T-tau and P-tau (S199, S396, T181
and T231) in CSF were detected by Enzyme-Linked
Immuno Sorbent Assay (ELISA). CSB-E10684h kit for
Aβ1-42 and CSB-E12011h kit for T-tau were from
CUSABIO Company (China). KHB7041 kit for P-tau
(S199), KHB7031 kit for P-tau (S396), KHO0631 kit for
P-tau (T181) and KHB8051 kit for P-tau (T231) were
from Invitrogen Company (USA).
Detection of neuroinflammatory factors
The levels of IL-6, IL-1β, TNF-α, INF-γ and PGE2 in
CSF were detected by ELISA. 1R140 kit for IL-6, 1R040
kit for IL -1β, 1R350 kit for TNF-α and 1R330 kit for
INF-γ were from RB Company (USA). CSB-E07965h kit
for PGE2 was from CUSABIO Company (China).
Detection of free radicals
The levels of hydroxyl radical (·OH), hydrogen peroxide
(H2O2) and nitric oxide (NO) in CSF were detected by
chemical colorimetric method. A018 kit for · OH, A064
kit for H2O2 and A012 kit for NO were from Nanjing
Jiancheng Biological Engineering Research Institute
(China).
Data analyses
Statistical analyses were performed with SPSS Statistics
20.0 (IBM Corporation, New York, USA). DemographicTable 1 Demographic information and disease features of con
Demographic information and disease features Control grou
(31 cases)
Age (years, mean ± SD) 52.2 ± 8.6
Gender (male/total, %) 17/31 (54.8%
Educational level
<6 years [case/total (%)] 11/31 (35.5%
6-12 years [case/total (%)] 15/31 (48.4%
>12 years [case/total (%)] 5/31 (16.1%)
Onset lateralization
Left [case/total (%)] -
Right [case/total (%)] -
Both [case/total (%)] -
Disease duration [years, median (quartile)] -
H-Y stage [stage, median (quartile)]information and the levels of pathological proteins, neu-
roinflammatory factors and free radicals in CSF from the
groups of control, PD-NCI and PD-CI were compared.
Continuous variables, if they were normally distributed,
were presented as means ± standard deviations and com-
pared by ANOVA test. Bonferroni correction was per-
formed in further comparisons between two groups, and
the corrected P value was significant when it was <0.025.
Continuous variables, if they were not normally distrib-
uted, were presented as median (quartile) and compared
by nonparametric test. Discrete variables were compared
by Chi square test. Spearman correlation analyses were
made between MoCA score and the level of each patho-
logical protein, neuroinflammatory factor and free radical
in CSF from groups of PD-NCI and PD-CI. P value was
significant when it was < 0.05.Results
Clinical features of cognitive impairment in PD patients
In the total 62 PD patients, 36 (58.1%) cases are with
PD-CI; 33 out of 36 PD-CI (53.2%) patients have MCI,
and the remaining 3 patients (4.8% of total) have PDD.
26 (41.9%) PD patients are without cognitive impairment.
In PD-CI group, cognitive domain with the lowest
scoring rate (actual score/total score) in MoCA is vocabu-
lary memory (14.7%), followed by abstraction (39.7%),
visuospatial and executive function (42.4%).
As shown in Table 1, there are significant differences
in age and educational level among three groups. Further
comparisons between two groups find that the average age
of PD-CI group is significantly higher than that of control
group (P = 0.006). Gender, onset lateralization, disease
duration and H-Y stage have no significant difference






57.4 ± 10.8 61.1 ± 9.4 0.019
) 13/26 (50.0%) 19/36 (52.8%) 0.483
0.045
) 5/26 (19.2%) 19/36 (52.8%)
) 16/26 (61.5%) 12/36 (33.3%)
5/26 (19.2%) 5/36 (13.9%)
0.544
11/26 (42.3%) 19/36 (52.8%)
13/26 (50.0%) 13/36 (36.1%)
2/26 (7.7%) 4/36 (11.1%)
2.0 (2.0 ~ 4.5) 3.0 (1.0 ~ 5.0) 0.834
2.0 (1.0 ~ 2.5) 2.0 (1.5 ~ 2.6) 0.128
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proteins in CSF and cognitive impairment in PD patients
Table 2 shows the comparisons of the levels of T-tau
and P-tau (S199, S396, T181 and T231) in CSF among
groups of control, PD-NCI and PD-CI. Further correl-
ation analysis indicates that MoCA score is negatively
correlated with the levels of T-tau (r = −0.340,P = 0.009)
and P-tau (S396) (r = −0.448, P = 0.036) in PD-CI patients.
However, the levels of Aβ1-42 show no significant correl-
ation with MoCA score.
The relationship between the levels of neuroinflammatory
factors in CSF and cognitive impairment in PD patients
Table 3 shows the comparisons of the levels of IL-6, IL-1β,
TNF-α, INF-γ and PGE2 among the groups of control,
PD-NCI and PD-CI. Correlation analysis indicates a sig-
nificantly negative linear correlation between MoCA score
and IL-6 level in CSF from PD-CI group (r = −0.489, P =
0.039). The levels of IL-1β, TNF-α, INF-γ and PGE2 are
not dramatically correlated with MoCA score. Consider-
ing the influence of age on the levels of neuroinflamma-
tory factors in CSF, we made further correlation analyses
between IL-6 level in CSF and age in both PD group and
PD-CI group, and find that the coefficients are not sig-
nificant in both groups (r = 0.184, P = 0.401; r = 0.111,
P = 0.731, respectively).
The relationship between the levels of free radicals in CSF
and cognitive impairment in PD patients
Table 4 shows the comparisons of the levels of ·OH,
H2O2 and NO among the groups of control, PD-NCI
and PD-CI. Correlation analysis indicates a significantly
negative linear correlation between MoCA score and ·OH
levels in CSF from PD-CI group (r = −0.504, P = 0.024).
The levels of H2O2 and NO in CSF are not dramatically
correlated with MoCA score in all groups.
Correlations of the levels of neuroinflammatory factors
and free radicals with pathological proteins in CSF from
PD patients
No significant correlations are found between the levels
of neuroinflammatory factors or free radicals and the
levels of pathological proteins in CSF from PD patients.Table 2 Comparisons of the levels of pathological proteins in
Pathological proteins Control group (31 cases) PD-NCI group (
T-tau (pg/ml) 39.209 (10.274 ~ 141.454) 95.991 (23.105 ~
P-tau (S199) (pg/ml) 3.426 ± 0.561 6.544 ± 1.
P-tau (S396) (pg/ml) 49.335 ± 26.215 71.059 ± 22
P-tau (T181) (pg/ml) 40.138 (30.722 ~ 53.644) 77.185 (49.271 ~
P-tau (T231) (pg/ml) 62.948 (46.241 ~ 80.793) 91.580 (87.163 ~
Aβ1-42 (ng/ml) 0.402 ± 0.082 0.432 ± 0.
P1: Control group vs. PD-NCI group; P2: Control group vs. PD-CI group, P3: PD-NCI gDiscussions
In this study, 58.1% PD patients had cognitive impairment,
which is roughly consistent with a result from another
study (57% at a mean of 3.5 years from PD diagnosis) [12],
demonstrating that cognitive impairment is a very com-
mon non-motor symptom in PD patients.
MoCA is a very sensitive scale for identifying the early
cognition decline in PD-CI patients. It has high test-
retest and inter-rater reliability and is notably correlated
with a neuropsychological battery. In this study, the
average scoring rate (actual score/total score) of MoCA
in PD patients is 64.8%. Based on the scoring rate of all
cognitive domains in MoCA from low to high level, dys-
function of vocabulary memory ranks the top in PD-CI
patients, which is reported to be associated with hippo-
campus atrophy [13]. Abstraction is the second domain
impaired significantly, followed by visuospatial and execu-
tive function. Disturbances of abstraction and executive
function are associated with the impairment of frontal-
striatal dopaminergic pathway [14]. Relationship between
executive dysfunction and visuospatial deficit in PD
patient is complicated [15]. Investigators have found that
statistically controlling deficits in executive skills through
analysis of covariance eliminates visuospatial impairment,
implying that executive dysfunction may account for
visuospatial impairment in PD subjects, however, statis-
tically controlling visuospatial deficits fails to alter ab-
normal executive function, indicating that visuospatial
dysfunction is independent of executive dysfunction in
PD [16]. Additionally, posterior brain regions are found
to be dominant for visuospatial ability [17].
Evidence shows that a short time to cognitive impair-
ment is associated with old age [18], which is confirmed
by our study. However, we find that educational level in
PD-NCI group is higher than that in PD-CI group, which
suggests that higher educational has a protective effect
against cognitive impairment [19]. Gender, disease dur-
ation and H-Y stage are not the contributors to PD-CI
in our study.
Increased T-tau level in CSF from patients with
Alzheimer’s disease and other neurodegenerative diseases
is widely thought to signify neuronal damage. However,
few studies focus on T-tau level in CSF and PD-CI. OneCSF among control, PD-NCI and PD-CI groups
26 cases) PD-CI group (36 cases) P1 P2 P3
125.394) 135.167 (41.261 ~ 175.683) 0.295 0.004 0.016
641 6.491 ± 1.579 0.000 0.000 1.000
.399 76.454 ± 33.340 0.037 0.001 0.607
95.730) 61.557 (55.461 ~ 84.649) 0.001 0.000 0.943
148.387) 101.746 (71.852 ~ 180.582) 0.001 0.000 0.749
103 0.416 ± 0.113 0.273 0.590 0.535
roup vs. PD-CI group.
Table 3 Comparisons of the levels of neuroinflammatory factors in CSF among control, PD-NCI and PD-CI groups
Neuroinflammatory factors Control group (31 cases) PD-NCI group (26 cases) PD-CI group (36 cases) P1 P2 P3
IL-6 (pg/ml) 1.414 ± 0.295 1.382 ± 0.307 1.716 ± 0.187 0.084 0.025 0.014
IL-1β (pg/ml) 17.078 (14.578 ~ 18.943) 19.522 (16.759 ~ 31.843) 19.625 (17.792 ~ 29.010) 0.050 0.000 0.870
TNF-α (pg/ml) 139.227 (78.938 ~ 168.261) 77.356 (34.580 ~ 180.960) 71.480 (36.467 ~ 147.145) 0.328 0.006 0.392
INF-γ (pg/ml) 9.067 ± 2.496 6.695 ± 1.712 6.601 ± 2.049 0.027 0.003 0.935
PGE2 (pg/ml) 6.105 (5.564 ~ 8.960) 6.550 (5.589 ~ 13.771) 6.973 (4.977 ~ 16.392) 0.337 0.730 0.775
P1: Control group vs. PD-NCI group; P2: Control group vs. PD-CI group, P3: PD-NCI group vs. PD-CI group.
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T-tau level in CSF and cognitive decline in PD patients
[20]. In this study, T-tau level in CSF in PD-CI group is
significantly enhanced comparing with control group
and PD-NCI group, and is increasingly elevated as cog-
nition declines in PD-CI group, suggesting that T-tau
may indicate the severity of PD-CI as a biomarker. P-tau is
found in AD patients, however, there is no research on the
relationship between P-tau level in CSF and PD-CI so far.
Here, the levels of P-tau (S199), P-tau (T181) and P-tau
(T231) in CSF in both PD-CI and PD-NCI groups are
significantly increased comparing with control group, but
there is no difference between PD-NCI group and PD-CI
group. These data imply that P-tau (S199), P-tau (T181)
and P-tau (T231) are more relevant to PD itself rather
than cognitive impairment. However, P-tau (S396) level is
significantly increased in PD-CI group comparing with
control group, and moreover, MoCA score is negatively
correlated with the level of P-tau (S396) in PD-CI group,
suggesting that P-tau (S396) may be indicative of cogni-
tion deterioration in PD patients.
A prospective study has found that a lower baseline
level of Aβ1–42 in CSF is associated with rapid cognition
decline in PD patients [20]. Aβ1–42 level in CSF from
PDD group is lower than non-demented PD and healthy
control groups [21]. We do not find an association be-
tween PD-CI and Aβ1–42 level in CSF. Pathologically,
PD-CI patients display the heterogeneity of amyloid-
related changes [22], which may be reflected by the dis-
crepancy in terms of the Aβ1–42 level in CSF. Data
from our investigation may support the pathological
heterogeneity of PD-CI in this group of patients, which
is featured by the significantly elevated levels of T-tau
and P-tau (S396) and the unchanged level of Aβ1–42.
Neuroinflammation featured by microglial activation
contributes to the cascade events leading to neuronalTable 4 Comparisons of the levels of free radicals in CSF amo
Free radicals Control group (31 cases) PD-NCI group (26 ca
OH (U/ml) 666.518 ± 97.447 726.447 ± 87.393
H2O2 (mmol/L) 1.973 (1.184 ~ 4.004) 1.973 (1.514 ~ 3.02
NO (mmol/L) 49.767 (25.912 ~ 60.850) 69.905 (33.194 ~ 108.
P1: Control group vs. PD-NCI group; P2: Control group vs. PD-CI group, P3: PD-NCI gdegeneration in PD [23]. Varies of endogenous and ex-
ogenous factors, such as α-synuclein and lipopolysacchar-
ide, activate microglia and produce a wealth of cytotoxic
neuroinflammatory factors, including IL-6, IL-1β, TNF-α
and INF-γ, etc. Neuroinflammatory factors exert toxic ef-
fects directly by binding to related receptors and activating
second messenger pathways, or indirectly by inducing
the expression of cyclooxygenase 2, a PGE2−generating
enzyme [23], promoting degeneration and death of dopa-
minergic neurons and subsequent occurrence of motor
symptoms.
Elevated levels of TNF-α [24], IL-1β [25] and IL-6 in
CSF from PD patients have been reported [26]. However,
role of neuroinflammation in the occurrence and develop-
ment of PD-CI is rarely conducted. Aging is a risk factor
for both PD and cognitive decline. Neuroinflammation
becomes severer with age [27] and may underlie the
cognitive disabilities in PD patients. Epidemiological data
indicate a slightly inverse relationship between TNF-α
level and cognitive function in the 50 to 60-year old of
healthy subjects [28]. Chronic inflammatory disease
exerts detrimental effects on cognitive function for per-
sons with chronic periodontal inflammation [29]. High
IL-1 level in hippocampus impairs learning ability [30].
Blocking IL-1 with receptor antagonist or knocking out
IL-1 in mice [31] attenuates cognitive dysfunction. These
data imply a potential correlation between neuroinflam-
mation and cognitive impairment. However, role of neuro-
inflammation on PD-CI are rarely conducted. A PET scan
with PK-11195, a ligand of peripheral binding site of
benzodiazepine indicative of microglial activation, re-
veals neuroinflammation in PD patients [32]. Cognitive
disorders-related cortical regions, including frontal and
temporal lobes, have increased binding of PK-11195.
Another study shows that PDD patients have signifi-
cantly higher level of C-reactive protein in CSF thanng control, PD-NCI and PD-CI groups
ses) PD-CI group (36 cases) P1 P2 P3
745.943 ± 93.861 0.080 0.005 0.582
8) 2.154 (1.973 ~ 7.864) 0.797 0.265 0.479
553) 68.481 (49.469 ~ 110.157) 0.024 0.000 0.530
roup vs. PD-CI group.
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gender and somatic illness [33]. In this study, IL-6 level
in CSF in PD-CI group is not only prominently en-
hanced comparing with PD-NCI group, but also has a
strikingly negative correlation with MoCA score, indi-
cating that IL-6 may be a potential neuroinflammatory
biomarker for the development and severity of cognitive
impairment in PD patients. Considering the influence of
age on the levels of neuroinflammatory factors in CSF,
we made further analyses between IL-6 level in CSF and
age in both PD group and PD-CI group, and find no
significant correlation, which suggest that the elevated
levels of neuroinflammatory factors are not resulted
from aging, and are closely associated with PD-CI.
However, neuroinflammation is a complex network, in
which each neuroinflammatory factor plays a different role
through acting on different receptors and/or by targeting
different signaling pathways at different stage. In this
study, TNF-α and INF-γ may play compensatory roles on
the deterioration of PD-CI since their levels in CSF in PD-
CI group are decreased comparing with control group.
However, the highly toxic effect of IL-6 may overweight
the potential compensatory effect of TNF-α and INF-γ,
leading to cognitive impairment eventually.
Oxidative stress characterized by robust generations of
free radicals plays a crucial role on neuronal damage in
PD. Upon a variety of stimuli, activation of microglial
nicotinamide adenine dinucleotide phosphate oxidase 2, a
superoxide-generating enzyme, produces a large amount
of superoxide very quickly. Superoxide can be synthesized
into H2O2, which induces the formation of fairly reactive
and toxic •OH radical in the presence of a high concentra-
tion of free iron, causing damage to neurons. Microglial
expression of inducible nitric oxide synthase leads to ex-
cessive NO generation [23]. Previous studies indicate an
important role of oxidative stress on cognitive impairment
in neurodegenerative diseases [7,8,34]; however, less at-
tention is paid to the role of free radicals on PD-CI. In
this investigation, •OH level in CSF in PD-CI group is
significantly increased comparing with control group,
and is negatively correlated with MoCA score, suggest-
ing a pivotal effect of oxidative stress in PD-CI and •OH
may be a potential indicator of PD-CI deterioration.
Both PD-CI group and PD-NCI group have drastically
higher NO levels in CSF than control group, implying
that NO is relevant to PD regardless of the existence of
cognitive impairment.
Correlations of the levels of neuroinflammatory factors
and free radicals with pathological proteins in CSF in
PD patients are not observed in this study. A variety of
stimuli can induce neuroinflammation and oxidative stress
in brain. Thus, pathological protein alone may not be suf-
ficient to elicit robust productions of neuroinflammatory
factors and free radicals in CSF.Conclusions
This study is the first part of our whole project and
mainly focuses on PD-MCI, thus, few PDD patients were
recruited within the limited time. We will enhance the
sample size of PDD patients and investigate the clinical
feature and potential mechanism of dementia in PD
patients in the very near future.
In summary, PD patients have a high incidence of cog-
nitive impairment, which mainly involves the cognitive
domains of vocabulary memory, abstraction, visuospatial
and executive function and language. The elevated levels
of T-tau, P-tau (S396), IL-6 and ·OH in CSF are signifi-
cantly correlated with PD-CI. This investigation may
suggest the potential biomarkers relating pathological
proteins, neuroinflammatory factors and free radicals in
PD patients with cognitive impairment.
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